2018 Section 6 - Laryngology, Voice Disorders, and Bronchoesophalogy
S. E. Attwood et al.
(a)
Omeprazole ( n = 92)
Open ARS ( n = 75)
2.5
2.5
2.0
2.0
1.5
1.5
1.0
1.0
0.5
0.5
0 0 0.5 1.0 1.5 Baseline S-ALP (relative to ULN) 2.5 2.0
0 0 0.5 1.0 1.5 Baseline S-ALP (relative to ULN) 2.5
S-ALP (relative to ULN), last value 2.0
S-ALP (relative to ULN), last value
Figure 3 | Serum levels of alkaline phosphatase (ALP) relative to the upper limit of normal (ULN) in individual patients treated with a proton pump inhibitor (omeprazole or esomeprazole) or anti-re fl ux surgery (open ARS or laparoscopic ARS [LARS]) in (a) the SOPRAN study (baseline vs. last value) and (b) the LOTUS study (baseline vs. 5 years). Diagonal line indicates ‘ no change ’ .
(b)
Esomeprazole ( n = 183)
LARS ( n = 147)
2.0
2.0
1.5
1.5
1.0
1.0
0.5
0.5
0 0 0.5 1.0 1.5 Baseline S-ALP (relative to ULN) 2.0
0 0 0.5 1.0 1.5 Baseline S-ALP (relative to ULN) 2.0
S-ALP (relative to ULN), 5-year
S-ALP (relative to ULN), 5-year
(a)
Omeprazole ( n = 143)
Open ARS ( n = 125)
5.0
5.0
4.0
4.0
3.0
3.0
2.0
2.0
1.0
1.0
0 0 1.0 2.0 3.0 Total baseline calcium (mmol/L) 4.0 5.0
0 0 1.0 2.0 3.0 Total baseline calcium (mmol/L) 4.0 5.0
Total calcium (mmol/L), last value
Total calcium (mmol/L), last value
(b)
Esomeprazole ( n = 182)
LARS ( n = 147)
Figure 4 | Serum levels of S- calcium in individual patients treated with a proton pump inhibitor (omeprazole or esomeprazole) or anti-re fl ux surgery (open ARS or laparoscopic ARS [LARS]) in (a) the SOPRAN study (baseline vs. last value) and (b) the LOTUS study (baseline vs. 5 years). Diagonal line indicates ‘ no change ’ .
5.0
5.0
4.0
4.0
3.0
3.0
2.0
2.0
1.0
1.0
0 0 1.0 2.0 3.0 Total baseline calcium (mmol/L) 4.0 5.0
0 0 1.0 2.0 3.0 Total baseline calcium (mmol/L) 4.0 5.0
Total calcium (mmol/L), last value
Total calcium (mmol/L), last value
Aliment Pharmacol Ther 2015; 41: 1162 – 1174 ª 2015 John Wiley & Sons Ltd
181
Made with FlippingBook HTML5